Loring Wolcott & Coolidge Fiduciary Advisors’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-50
| Closed | -$456 | – | 554 |
|
|
2025
Q2 | $456 | Hold |
50
| – | – | ﹤0.01% | 514 |
|
|
2025
Q1 | $381 | Hold |
50
| – | – | ﹤0.01% | 549 |
|
|
2024
Q4 | $372 | Hold |
50
| – | – | ﹤0.01% | 550 |
|
|
2024
Q3 | $393 | Hold |
50
| – | – | ﹤0.01% | 564 |
|
|
2024
Q2 | $608 | Hold |
50
| – | – | ﹤0.01% | 545 |
|
|
2024
Q1 | $645 | Hold |
50
| – | – | ﹤0.01% | 556 |
|
|
2023
Q4 | $1.28K | Hold |
50
| – | – | ﹤0.01% | 540 |
|
|
2023
Q3 | $978 | Hold |
50
| – | – | ﹤0.01% | 593 |
|
|
2023
Q2 | $2.35K | Hold |
50
| – | – | ﹤0.01% | 607 |
|
|
2023
Q1 | $2.1K | Hold |
50
| – | – | ﹤0.01% | 573 |
|
|
2022
Q4 | $1.91K | Hold |
50
| – | – | ﹤0.01% | 554 |
|
|
2022
Q3 | $2K | Hold |
50
| – | – | ﹤0.01% | 585 |
|
|
2022
Q2 | $2K | Hold |
50
| – | – | ﹤0.01% | 616 |
|
|
2022
Q1 | $2K | Hold |
50
| – | – | ﹤0.01% | 619 |
|
|
2021
Q4 | $2K | Hold |
50
| – | – | ﹤0.01% | 699 |
|
|
2021
Q3 | $2K | Hold |
50
| – | – | ﹤0.01% | 716 |
|
|
2021
Q2 | $3K | Buy |
+50
| New | +$3.53K | ﹤0.01% | 812 |
|
|
2021
Q1 | – | Sell |
-50
| Closed | -$4K | – | 619 |
|
|
2020
Q4 | $4K | Hold |
50
| – | – | ﹤0.01% | 713 |
|
|
2020
Q3 | $3K | Hold |
50
| – | – | ﹤0.01% | 564 |
|
|
2020
Q2 | $2K | Hold |
50
| – | – | ﹤0.01% | 567 |
|
|
2020
Q1 | $1K | Hold |
50
| – | – | ﹤0.01% | 636 |
|
|
2019
Q4 | $4K | Hold |
50
| – | – | ﹤0.01% | 621 |
|
|
2019
Q3 | $7K | Hold |
50
| – | – | ﹤0.01% | 593 |
|
|
2019
Q2 | $9K | Hold |
50
| – | – | ﹤0.01% | 570 |
|
|
2019
Q1 | $8K | Hold |
50
| – | – | ﹤0.01% | 572 |
|
|
2018
Q4 | $5K | Hold |
50
| – | – | ﹤0.01% | 601 |
|
|
2018
Q3 | $7K | Hold |
50
| – | – | ﹤0.01% | 552 |
|
|
2018
Q2 | $8K | Hold |
50
| – | – | ﹤0.01% | 561 |
|
|
2018
Q1 | $8K | Hold |
50
| – | – | ﹤0.01% | 597 |
|
|
2017
Q4 | $8K | Hold |
50
| – | – | ﹤0.01% | 584 |
|
|
2017
Q3 | $3K | Hold |
50
| – | – | ﹤0.01% | 620 |
|
|
2017
Q2 | $4K | Buy |
+50
| New | +$3.62K | ﹤0.01% | 599 |
|
Other funds holding SAGE
IA
HNB
Loring Wolcott & Coolidge Fiduciary Advisors's SAGE Position: Q3 2025 in Review
Loring Wolcott & Coolidge Fiduciary Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 50 shares — an estimated $456 sold.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in SAGE in Q2 2017 and held it in 32 quarters. The position peaked at $9K in Q2 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 50 Sage Therapeutics shares in Q3 2025, an estimated $456.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Sage Therapeutics in Q2 2017 and held it in 32 quarters.
- Loring Wolcott & Coolidge Fiduciary Advisors's Sage Therapeutics position peaked at $9K in Q2 2019.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.